NCT01359579View on ClinicalTrials.gov

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

PHASE1TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

June 30, 2012

Conditions
Renal Impairment
Interventions
DRUG

varespladib methyl

Single oral 500 mg dose

Trial Locations (3)

32809

Investigator Site 101, Orlando

37920

Investigator Site 103, Knoxville

55404

Investigator Site 102, Minneapolis

Sponsors
All Listed Sponsors
lead

Anthera Pharmaceuticals

INDUSTRY

NCT01359579 - A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function | Biotech Hunter | Biotech Hunter